GLUE

Monte Rosa Therapeutics, Inc.

3.00 USD

Last updated Dec 6, 00:24 UTC

Yesterday HIGH

$3.2

Yesterday LOW

$2.99

52w HIGH

$9.72

52w LOW

$2.44

EPS

-0.7

PE

-4.29

Next Earnings

Mar 14, 2024

Overview News Government Trades

Monte Rosa Therapeutics, Inc. stock is down -9.64% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.

Monte Rosa Therapeutics, Inc. engages in the development of novel small molecule precision medicines. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

monterosatx.com

Michael Horton

Mon Apr 17, 2023

Monte Rosa Therapeutics Presents Preclinical Data From GSPT1 Degrader Program Focused On MYC-Driven Cancers At AACR 2023
richadhand@benzinga.com

Fri Mar 17, 2023

Credit Suisse Maintains Neutral on Monte Rosa Therapeutics, Lowers Price Target to $11

Credit Suisse analyst Richard Law maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Neutral and lowers the price target from $12 to $11.
Benzinga Insights

Fri Mar 10, 2023

Stocks That Hit 52-Week Lows On Friday

On Friday, 497 companies set new 52-week lows.
Lisa Levin

Mon Jan 9, 2023

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Charles Gross

Mon Jan 9, 2023

Monte Rosa Therapeutics Outlined Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today outlined anticipated 2023 milestones ahead of its participation at the 41st Annual J.P. Morgan Healthcare Conference.
Benzinga Newsdesk

Tue Jan 3, 2023

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target

Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and announces $19 price target.
Lisa Levin

Mon Nov 14, 2022

Dow Surges 150 Points; Crude Oil Falls Sharply

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
Benzinga Newsdesk

Thu Nov 10, 2022

Monte Rosa Therapeutics Q3 EPS $(0.58) Down From $(0.43) YoY

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.58) per share. This is a 34.88 percent decrease over losses of $(0.43) per share from the same period last year.
Benzinga Newsdesk

Tue Nov 1, 2022

Monte Rosa Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Evaluating MRT-2359, A GSPT1-directed Molecular Glue Degrader, For Treatment Of MYC-driven Tumors

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical
Benzinga Insights

Mon Oct 17, 2022

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.